Biotech News
Related news
SUPNSupernus2026-08-03 10:30 EST
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
SUPNSupernus2026-07-22 21:05 EST
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
TNXPTonix Pharmaceuticals2026-08-05 11:00 EST
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
ANNXAnnexon, Inc.2026-05-27 12:00 EST
Annexon to Participate in Upcoming June Investor Conferences
ECORelectroCore2026-08-03 12:00 EST
electroCore to Participate in Upcoming Investor Conferences
HRMYHarmony Biosciences2026-05-27 12:05 EST
Harmony Biosciences to Participate in Upcoming Investor Conferences
AXSMAxsome2026-05-27 11:00 EST
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NBIXNeurocrine Biosciences2026-05-26 20:01 EST
Neurocrine Biosciences to Present at Upcoming Investor Conferences in June
CGTXCognition Therapeutics2026-06-01 11:30 EST
Cognition Therapeutics Participating in Upcoming Investor Conferences
ABOSAcumen Pharmaceuticals2026-08-12 11:00 EST
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
Supernus
CNS Commercial Portfolio Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Growth Products The company’s...
Recent company news
SUPNSupernus2026-08-03 10:35 EST
Supernus Announces Second Quarter 2026 Financial Results
SUPNSupernus2026-08-03 10:30 EST
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
SUPNSupernus2026-07-22 21:05 EST
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
SUPNSupernus2026-07-14 12:30 EST
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
SUPNSupernus2026-05-27 20:30 EST
Supernus Pharmaceuticals to Participate in June Investor Conferences
Stock data
- Close
- 45.85 USD
- Market cap
- 2.56B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States